A call to reduce the incidence of Alzheimer's disease

Journal of Applied Research

Volumn 10, Issue 2, 2010, Pages 53-57

  Waugh, William H ^a,b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Alzheimer's disease; Mild cognitive impairment sodium R lipoate; Vitamin C

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; DEFEROXAMINE; DIHYDROLIPOATE; PLACEBO; SODIUM; THIOCTIC ACID; TRACE ELEMENT;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; AMNESIA; ANTIOXIDANT ACTIVITY; ARTICLE; BIOENERGY; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; INCIDENCE; IRON CHELATION; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MITOCHONDRIAL MEMBRANE; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; PREVALENCE; RACEMIC MIXTURE; RECOMMENDED DRUG DOSE; STEREOISOMERISM;

EID: 77954984190     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons higher than previously reported. JAMA. 1989;262:2551-2556.
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
3. Querfurth HW, LaFerla FM. Mechanisms of disease Alzheimer's disease. N Engl J Med. 2010;362,329-344.
4. Nunomura A, Castellani RJ, Zhu X, et al. Involvement of oxidative stress in Alzheimer disease. J Neuropath Exp Neurol. 2006;631-641.
5. Markesbery WE, Lovell MA. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol. 2007;64:954-956.
6. Espeland MA, Henderson VW. Preventing cognitive decline in usual aging. Arch Intern Med. 2006;166:2433-2434.
7. Waugh WH. Cognitive decline therapy by iron burden reduction. Arch Intern Med. 2007;167:1098. [letter to the editor].
8. Goodman J. Alzheimer's disease a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Mental Dis 1953;117:97-130.
9. Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation in Alzheimer's disease ia a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866-9868.
10. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci 2004;1012:179-182.
11. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypothesis. 2004;63:8-20.
12. Mecocci P, Macgarvey U, Kaufman AE, et al. Oxidative damage to mitochondrial DNA shows marked age -dependent increases in human brain. Ann Neurol. 1993;34:609-616.
13. Practico D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal: Trends Pharmacol Sci. 2006;41:609-615.
14. Van Gool WA, Weinsttein HC, Scheltens, Walstra GJM. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomized, double-blind, placebocontrolled study. Lancet. 2001;358:455-460.
15. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatrics. 2001;32:275-282.
16. Ono K, Hirochata M, Yamada M. Alpha-lipoic acid exhibits anti-amyloidogenicity for beta-amyloid fibrils in vitro. Biochem Biophys Res Commun. 2006;341:1046-1052.
17. Hagan TM, Ingersoll RT, Lykkesfeldt J, et al. (R)-ά-lipoic acid supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J. 1999;13:411 -418.
18. Zimmer G, Mainka L, Kruger E. Dihydrolipoic acid activates oligomycin-sensitive thiol groups and increases ATP synthesis in mitochondria. Arch Biochem Biophys. 1991;288:609-613.
19. Lynch MA. Lipoic acid confers protection against oxidative injury in non-neuronal and neuronal tissue. Nutr Neurosci. 2001;4:419-438.
20. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 2004;11:1135-1146.
21. Jacob S, Rett K, Henrikisen EJ, Haring H-U. Thiotic acid - effects on insulin sensitivity and glucose -metabolism. BioFactors 1999;10:169-174.
22. Simic MC, Jovanovic SV. Antioxidation mechanisms of uric acid. J Am Chem Soc. 1989;111 5778-5782.
23. Waugh WH. Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid levels: therapeutic implications for Alzheimer's disease and late cognitive impairment. Gerontology. 2008;54 238.
24. Halliwell B. Oxidants and the central nervous system: some fundamental questions is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand. 1989;126:23-33.
25. Holmquist L, Stuchbury G, Bermbaum K, et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther. 2007:113:154-164.
26. Schipper HM, Cisse S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer diseased-brain. Ann Neurol 1995;37:758-768.
27. Li C, Hossieny P, Wu BJ, Qawasmeh A, Beck K, Stocker R. Pharmacologic induction of heme oxygenase-1. Antioxid Redox Signal. 2007;9:2227-2239.
28. Lykkesfeldt J, Hagen TM, Vinarsky V, Ames BN. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes - reversal with (R)-ά-lipoic acid supplementation. FASEB J. 1998;12:1183-1189.
29. Liu J, Head E, Grarib AM et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-l-carnitine and/or (R)-ά-lipoic acid. Proc Natl Acad Sci USA. 2002;99:2356-2361.
30. Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: Improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-l -carnitine and/or (R)-ά-lipoic acid. Proc Natl Acad Sci USA. 2002;99:1876-1881.
31. Suh JH, Moreau R, Heath S-H D, Hagen TM. Dietary supplementation with (R)-α-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005;10:52-60.
32. Suh JH, Zhu B-Z, deSzoeke E, Frei B, Hagen TM. Dihydrolipoic acid lowers the redox activity of transition metal ions but does not remove them from the active site of enzymes. Redox Rep. 2004;9:57-61.
33. Riviere S, Biriouez-Aragon I, Nourhashemi F, Velas B. Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry. 1998;13:749-754.
34. Teichert J, Kem J, Tritscher HJ, Ulrich H, Preiss R. Investigations on the pharmacokinetics of alpha -lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther. 1998;36:625-628.
35. Teichert J, Hermann R, Russ P, Preiss R. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J Clin Pharmacol 2003;43:11:1257-1267.
36. Carlson DA, Smith AR, Fischer SJ, Young KL, Packer L. The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects. Altern Med Rev. 2007;12 343-351.
37. Mecocci P, Polidori C, Cherubini A, et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer's disease. Arch Neurol. 2002;57:794-798.
38. Crapper McLachlan DR, Dalton AJ, Kruck TPA, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 1991;337:1304-1307.
39. Smith MA, Zhu X, Tabaton M, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimer's Disease. 2010;19:363-372.
40. Hager K, Kenklies M, McAfoose J, Engel J, Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease--48 months follow-up analysis. J Neural Transm Suppl. 2007;72:189-193.